Bruker Co. (NASDAQ:BRKR) Receives $70.50 Average PT from Analysts

Shares of Bruker Co. (NASDAQ:BRKR) have been given an average recommendation of “Moderate Buy” by the eleven analysts that are presently covering the firm, Marketbeat reports. Five equities research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $70.50.

A number of research firms have weighed in on BRKR. The Goldman Sachs Group upgraded Bruker from a “sell” rating to a “neutral” rating and set a $60.00 target price on the stock in a report on Thursday, December 5th. Citigroup reduced their target price on Bruker from $80.00 to $75.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Wells Fargo & Company reduced their target price on Bruker from $78.00 to $75.00 and set an “overweight” rating on the stock in a report on Wednesday, November 6th. Stifel Nicolaus cut their price target on Bruker from $70.00 to $57.00 and set a “hold” rating on the stock in a research note on Friday, February 14th. Finally, Bank of America upped their price target on Bruker from $78.00 to $80.00 and gave the stock a “buy” rating in a research note on Friday, December 13th.

Bruker Stock Down 4.0 %

Shares of NASDAQ:BRKR opened at $50.82 on Friday. Bruker has a 1 year low of $48.07 and a 1 year high of $94.86. The stock’s 50-day moving average is $56.73 and its 200 day moving average is $60.03. The company has a debt-to-equity ratio of 1.15, a current ratio of 1.60 and a quick ratio of 0.77. The company has a market cap of $7.70 billion, a PE ratio of 66.87, a P/E/G ratio of 2.16 and a beta of 1.16.

Bruker (NASDAQ:BRKR) last posted its earnings results on Thursday, February 13th. The medical research company reported $0.76 earnings per share for the quarter, topping analysts’ consensus estimates of $0.75 by $0.01. Bruker had a return on equity of 21.01% and a net margin of 3.36%. Sell-side analysts anticipate that Bruker will post 2.69 EPS for the current year.

Hedge Funds Weigh In On Bruker

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Wealth Enhancement Advisory Services LLC lifted its position in Bruker by 1.4% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 13,287 shares of the medical research company’s stock valued at $779,000 after acquiring an additional 177 shares in the last quarter. Quadrant Capital Group LLC lifted its position in Bruker by 18.2% in the 4th quarter. Quadrant Capital Group LLC now owns 1,273 shares of the medical research company’s stock valued at $75,000 after acquiring an additional 196 shares in the last quarter. Insigneo Advisory Services LLC lifted its position in Bruker by 4.7% in the 4th quarter. Insigneo Advisory Services LLC now owns 4,880 shares of the medical research company’s stock valued at $286,000 after acquiring an additional 218 shares in the last quarter. Arizona State Retirement System lifted its position in Bruker by 0.7% in the 4th quarter. Arizona State Retirement System now owns 30,725 shares of the medical research company’s stock valued at $1,801,000 after acquiring an additional 222 shares in the last quarter. Finally, CIBC Asset Management Inc lifted its position in Bruker by 5.6% in the 4th quarter. CIBC Asset Management Inc now owns 4,233 shares of the medical research company’s stock valued at $248,000 after acquiring an additional 223 shares in the last quarter. 79.52% of the stock is owned by institutional investors.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.